Xtant Medical Holdings, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a XTNT research report →
Companywww.xtantmedical.com
Xtant Medical Holdings, Inc. develops, manufactures, and markets regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. Its biomaterial products include OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSponge SC that fills bony defects in the subchondral region of joints; OsteoSelect DBM Putty for osteoinductive bone growth; OsteoSelect PLUS DBM Putty for use as a bone void filler and bone graft substitute in the pelvis, extremities, and posterolateral spine; OsteoFactor, which contains various proteins and peptides that support bone formation and remodeling; OsteoWrap; and OsteoVive Plus, a growth factor enriched cellular bone matrix.
- CEO
- Sean E. Browne
- IPO
- 2010
- Employees
- 217
- HQ
- Belgrade, MT, US
Price Chart
Valuation
- Market Cap
- $66.25M
- P/E
- 36.17
- P/S
- 0.54
- P/B
- 1.36
- EV/EBITDA
- 6.12
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 62.34%
- Op Margin
- 2.71%
- Net Margin
- 1.50%
- ROE
- 3.68%
- ROIC
- 2.41%
Growth & Income
- Revenue
- $133.93M · 14.21%
- Net Income
- $4.97M · 130.23%
- EPS
- $0.04 · 133.33%
- Op Income
- $7.28M
- FCF YoY
- 163.49%
Performance & Tape
- 52W High
- $0.95
- 52W Low
- $0.44
- 50D MA
- $0.53
- 200D MA
- $0.64
- Beta
- -0.12
- Avg Volume
- 150.97K
Get TickerSpark's AI analysis on XTNT
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 15, 26 | Schallenberger Mark A. | other | 7,709 |
| Jan 15, 26 | Neils Scott C | other | 8,084 |
| Nov 15, 25 | BAKEWELL JOHN K | other | 158,228 |
| Nov 15, 25 | Vizirgianakis Stavros G. | other | 553,797 |
| Nov 15, 25 | Beeson Jonn R. | other | 158,228 |
| Nov 15, 25 | BAKEWELL JOHN K | other | 158,228 |
| Nov 15, 25 | JAIN ABHINAV | other | 158,228 |
| Nov 15, 25 | Lipschultz Tyler | other | 158,228 |
| Nov 15, 25 | Browne Sean E | other | 394,937 |
| Nov 15, 25 | Browne Sean E | other | 789,874 |
Our XTNT Coverage
We haven't published any research on XTNT yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate XTNT Report →